Study to evaluate the effect of Triphala Kashayam with and without diet and lifestyle modifications in patients with gout.

A comprative clinical study of triphala kashayam with and Without pathya-apathya regimen in the management of Vatarakta with special reference to Gout. - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/06/112626

Enrollment

Registered

2026-06-12

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M109- Gout, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed cases of Gout (Vatarakta) based on classical Ayurvedic signs and symptoms such as- Joint pain (Sandhi Vedana) Swelling (Shotha) Redness (Raga) Tenderness Burning sensation (Daha) Stiffness (Stambha) -Serum uric acid level- more than 7.0 mg/dL in males or more thna 6.0 mg/dL in females

Exclusion criteria

Exclusion criteria: Patients suffering from: Rheumatoid Arthritis Chronic Kidney Disease Uncontrolled diabetes mellitus Patients receiving: Corticosteroids Allopurinol Febuxostat Other uric acid-lowering drugs within the previous 1 month. Pregnant women. Lactating mothers. Patients with severe systemic illness (hepatic, cardiac, malignant, or other serious disorders). Patients unwilling to participate or unable to comply with study procedures. Patients requiring emergency treatment during the study period

Design outcomes

Primary

Measure	Time frame
Mean change in Serum Uric Acid Level (mg/dL) from baseline after administration of Triphala Kashayam with and without Pathya Apathya regimenTimepoint: Day 15, Day 30, Day 45, and Day 60 for clinical parameters; Day 30 and Day 60 for laboratory parameters; Baseline and Day 60 for safety assessment.	—

Secondary

Measure	Time frame
-Change in pain (Vedana), swelling (Shotha), tenderness, redness (Raga), burning sensation (Daha), stiffness (Stambha), and difficulty in walking/joint movement scores from baseline. -Change in ESR and CRP levels from baseline. -Assessment of treatment safety through Kidney Function Test (KFT) and monitoring of adverse events.Timepoint: Day 15, Day 30, Day 45, and Day 60 for clinical parameters; Day 30 and Day 60 for laboratory parameters; Baseline and Day 60 for safety assessment.	—

Measure

Time frame

-Change in pain (Vedana), swelling (Shotha), tenderness, redness (Raga), burning sensation (Daha), stiffness (Stambha), and difficulty in walking/joint movement scores from baseline. -Change in ESR and CRP levels from baseline. -Assessment of treatment safety through Kidney Function Test (KFT) and monitoring of adverse events.Timepoint: Day 15, Day 30, Day 45, and Day 60 for clinical parameters; Day 30 and Day 60 for laboratory parameters; Baseline and Day 60 for safety assessment.

—

Countries

India

Contacts

Public ContactDr Niraj Kumar

Government Ayurvedic College and Hospital, Patna

drpsunita@gmail.com9431259606

Outcome results